Project Grant R01HL173533
Award Date
9/15/24
Completion Date
6/30/29
Dollars Obligated
$2.1M
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Philadelphia, PA 19104, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837) provides $1,617,792.00 to The Leland Stanford Junior University to conduct research on the role of the carboxylesterase 1 (CES1) enzyme in the development and progression of pulmonary arterial hypertension (PAH). The research aims to determine how loss of CES1 leads to metabolic reprogramming, lipotoxicity, and oxidative stress in...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $244,589 to support research on the role of the protein VPS34 in the development and progression of pulmonary arterial hypertension (PAH). The primary research aims are to: 1) examine the regulation and activation of VPS34 in the pulmonary vasculature of PAH patients, 2) determine the impact of VPS34 on the proliferation and...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $633,045 to the University of Pittsburgh to investigate the pathogenic mechanisms and therapeutic approaches for exercise intolerance in patients with post-acute sequelae of COVID-19 (PASC). The research aims to: 1) evaluate the predictive value of angiotensin-converting enzyme 2 (ACE2) activity as a biomarker for exercise...
The National Heart Lung and Blood Institute (NHLBI) awarded a $164,700 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to The Trustees of the University of Pennsylvania, doing business as the Clinical Practices of the University of Pennsylvania, to study the role of mTOR hyperactivation in pulmonary vascular remodeling. The research aims to examine how mTOR activation in specific mesenchymal cell populations alters endothelial cell behavior and function, and how aberrant mTOR...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $2,323,125.00 in funding to the University of California, Los Angeles (UCLA) to investigate the role of the RNA-binding protein ZFP36 in the pathogenesis of pulmonary arterial hypertension (PAH). The research aims to use large-scale transcriptomic data and computational biology to identify the targets of ZFP36 and characterize their...
This Project Grant award of $539,218.00 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) will support research to develop and validate a prediction model for progression-free survival in patients with myositis-associated interstitial lung disease (ILD). The research aims to identify novel biomarkers and subphenotypes to better understand the clinical and biological heterogeneity of myositis-ILD. The award was granted to The Trustees of the...
The federal Project Grant award R01HL176673, funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to determine the molecular mechanisms by which the protein factor Response Gene to Complement 32 (RGC-32) regulates endothelial-mesenchymal transition (EndoMT) of pulmonary artery endothelial cells and its role in the development of pulmonary arterial hypertension (PAH). The $658,885 award, with a...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $692,768 to Rhode Island Hospital to study pulmonary arterial hypertension (PAH). The research aims to characterize endothelial cell dysfunction and anoikis resistance in PAH, using a novel "cell biopsy" method to harvest and analyze endothelial cells from pulmonary artery catheters. The project will define molecular mechanisms underlying PAH,...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837), provides $325,080 to The Trustees of the University of Pennsylvania to conduct research on aging and metabolic dysfunction in pulmonary fibrosis. The key products and services to be delivered through this one-year award include: 1) in-vivo application of the SFTPC173T fibrosis model to characterize the impact of aging on...
This $102,932 federal Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to identify clinically accessible metrics that can serve as surrogates for right ventricular-pulmonary arterial (RV-PA) coupling and indicators of RV adaptation in pulmonary arterial hypertension (PAH). The proposed research aims to: 1) develop a multivariable model to identify clinically available metrics as...